Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder: A Systematic Review

Coghill, David · 2010 · CNS Drugs

Abstract

Quality of life (QOL) describes an individual's subjective perception of their position in life as evidenced by their physical, psychological and social functioning. Although an established outcome measure in physical health, QOL has more recently become an increasingly important measure in mental health clinical work and research. This article reviews the evidence describing the impact of medications on QOL in attention-deficit hyperactivity disorder (ADHD). Databases were searched for research studies describing the effects of medication on QOL in ADHD: 25 relevant studies were identified. Most (n = 20) of these studies have focused on children and adolescents, and most have investigated a single molecule, atomoxetine (n = 15), with relatively few studies investigating methylphenidate (n = 5), amfetamines (n = 4) and manifaxine (n = 1). These studies support a positive short-term effect of medication on QOL in ADHD for children, adolescents and adults that mirrors, to some extent, the effects of these medications on ADHD symptoms, although with smaller effect sizes. Notwithstanding measurement issues, it will continue to be important that those designing and conducting clinical trials in ADHD, including both pharmacological and non-pharmacological treatments, continue to include measures of QOL as secondary outcome measures. In particular, information about QOL effects in adults and in subjects of all ages taking methylphenidate and amfetamine treatments is urgently needed. The lack of systematic studies of the impact on QOL of psychological therapies, either on their own or in multimodal combinations with medication, is a serious omission that should be urgently addressed.

Overview

Integrity signals

Registry

Crossref · 10.2165/11537450-000000000-00000

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 85 references

Research works printed but not linked: 8

  1. Erhardt, 1994, J Consult Clin Psychol, 62, 833, 10.1037/0022-006X.62.4.833 · doi:10.1037/0022-006x.62.4.833 · Paper page
  2. Pongwilairat, 2005, J Med Assoc Thailand, 88, 1062
  3. Hampel, 2006, Prax Kinderpsychol Kinderpsychiatr, 55, 425
  4. Brod, 2005, Prim Psychiatry, 12, 58
  5. Rentz, 2005, Qual Life Res, 14, 719, 10.1007/s11136-004-0832-9 · DOI
  6. 1985, Psychopharmacol Bull, 21, 839
  7. Sallee, 2004, J Outcome Res, &NA;, 27
  8. Norman, 2003, Med Care, 41, 582

Cited by

See all 103

Metadata

Authors
Coghill, D.
Affiliations
University of Dundee (GB)
Corresponding author
Coghill, David
Venue
CNS Drugs
Published
2010-10
Volume
24
Issue
10
Pages
843-866
ISSN
1172-7047 (ISSN-L)
OpenAlex
W25938887
Cited by
103
References
85
Citations by year
2026: 2 · 2025: 5 · 2024: 10 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 9 · 2016: 6 · 2015: 12 · 2014: 6 · 2013: 15 · 2012: 7
FWCI
1.22
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
attention deficit hyperactivity disorder, quality of life, ADHD medication, atomoxetine, methylphenidate, amphetamine, children and adolescents, adults, secondary outcome measures, psychotherapy
MeSH terms
Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Quality of Life, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder: A Systematic Review. https://app.cochat.ai/papers/10.2165/11537450-000000000-00000
The paper
Coghill, D. (2010). The Impact of Medications on Quality of Life in Attention-Deficit Hyperactivity Disorder: A Systematic Review. CNS Drugs. https://doi.org/10.2165/11537450-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.